Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Equinox's GLP-1 protocol is considered a framework for people taking the drugs, one that addresses workout intensity, ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

“Ozempic face” refers to the sagging of skin due to rapid weight loss. Experts say it’s preventable by slowing down weight ...

I n addition to their origins as treatment for type 2 diabetes, GLP-1 receptor agonists like Ozempic and Wegovy are often ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...